Worldwide Consumer Sales

$13.3B

Adjusted, operational worldwide sales increase 4.3%*

Primary contributors:

- Tylenol®
- imodium®
- Neutrogena®
- Aveeno®
- Listerine®

Worldwide Pharmaceutical Sales

$33.5B

Adjusted, operational worldwide sales increase 11.5%*

Products that contributed to growth:

- Remicade®
- Simponi®
- Imodium®
- Invega®
- Stelara®

Worldwide Medical Devices Sales

$25.1B

Adjusted, operational worldwide sales increase 3.8%*

Primary contributors:

- Complete Heart Restore
- Xomed
- Stryker
- Sensus
- Synovis
- Spine Solutions
- Acclarent
- ACUVUE® Contact Lenses
- Rebalance
- Joint Reconstruction

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Adjusted operational sales growth excludes the net impact of acquisitions, divestitures, hepatitis C sales, Venezuela and the impact of additional shipping days in 2015. Reported full-year 2016 diluted earnings per share was $5.93, reported worldwide consumer sales increased 4.3%, reported pharmaceutical sales increased 6.5% and reported medical devices sales decreased 0.1%. For all full-year data and non-GAAP reconciliations, please refer to the Johnson & Johnson’s earnings release issued on January 24, 2017, available at http://www.investor.jnj.com/sales-earnings.cfm.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson’s earnings release issued on January 24, 2017, as well as the Johnson & Johnson Annual Report for the fiscal year ended January 3, 2016. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

"We are pleased to report that we accelerated our adjusted growth for 2016 over the prior year, and delivered a strong total shareholder return of greater than 15 percent. The strong adjusted sales and EPS growth was driven by the impressive performance of our Pharmaceutical business and continued momentum in our Medical Device business and share gains while improving profitability in our Consumer business. Looking forward to 2017, we expect to continue driving sustainable, long-term growth through the new products, science and innovation that our talented colleagues and partners at Johnson & Johnson are advancing to positively impact human health."